首页> 外文期刊>Archives of medical research >Hematopoietic Support Capacity of Mesenchymal Stem Cells: Biology and Clinical Potential
【24h】

Hematopoietic Support Capacity of Mesenchymal Stem Cells: Biology and Clinical Potential

机译:间充质干细胞的造血支持能力:生物学和临床潜力。

获取原文
获取原文并翻译 | 示例
           

摘要

Mesenchymal stem cells (MSCs) play an important role in the physiology and homeostasis of the hematopoietic system. Because MSCs generate most of the stromal cells present in the bone marrow (BM), form part of the hematopoietic stem cell (HSC) niche, and produce various molecules regulating hematopoiesis, their hematopoiesis-supporting capacity has been demonstrated. In the last decade, BM-MSCs have been proposed to be useful in some ex vivo protocols for HSC expansion, with the aim of expanding their numbers for transplant purposes (HSC transplant, HSCT). Furthermore, application of MSCs has been proposed as an adjuvant cellular therapy for promoting rapid hematopoietic recovery in HSCT patients. Although the MSCs used in preliminary clinical trials have come from the BM, isolation of MSCs from far more accessible sources such as neonatal tissues has now been achieved, and these cells have been found to possess similar biological characteristics to those isolated from the BM. Therefore, such tissues are now considered as a potential alternative source of MSCs for clinical applications. In this review, we discuss current knowledge regarding the biological characteristics of MSCs as related to their capacity to support the formation of hematopoietic stem and progenitor cells. We also describe MSC manipulation for ex vivo HSC expansion protocols used for transplants and their clinical relevance for hematopoietic recovery in HSCT patients. (C) 2015 IMSS. Published by Elsevier Inc.
机译:间充质干细胞(MSCs)在造血系统的生理和稳态中起着重要作用。由于MSC会生成大多数存在于骨髓(BM)中的基质细胞,形成造血干细胞(HSC)小生境的一部分,并产生各种调节造血功能的分子,因此已证明它们具有造血功能。在过去的十年中,已经提出了BM-MSC在某些用于HSC扩增的离体方案中是有用的,目的是为了出于移植目的(HSC移植,HSCT)而扩大其数量。此外,已经提出了MSC的应用作为辅助细胞疗法,以促进HSCT患者的快速造血恢复。尽管在初步临床试验中使用的MSC来自BM,但现已实现了从更容易获得的来源(如新生儿组织)中分离MSC,并且发现这些细胞具有与从BM分离的细胞相似的生物学特性。因此,这些组织现在被认为是用于临床应用的MSC的潜在替代来源。在这篇综述中,我们讨论了有关MSC生物学特性的当前知识,这些知识与它们支持造血干细胞和祖细胞形成的能力有关。我们还描述了用于移植的离体HSC扩展方案的MSC操作及其与HSCT患者造血恢复的临床相关性。 (C)2015年IMSS。由Elsevier Inc.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号